Court Opinion

ID: 4648826
Source: CourtListenerOpinion
Date Created: 2021-01-04 18:01:47.381345+00
Date Added: 2024-06-11T08:01:18.888409
License: Public Domain

In the United States Court of Federal Claims
                                    OFFICE OF SPECIAL MASTERS
                                            No. 19-749V
                                         (not to be published)

*********************                                            Chief Special Master Corcoran
J.N.H.,                     *
by his parents,             *
JOHN HEATH and MARIE        *
LOUISE HEATH,               *
                            *
                Petitioner, *                                    Filed: November 16, 2020
                            *
v.                          *
                            *                                    Autism Spectrum Disorder; Attorney’s
SECRETARY OF HEALTH         *                                    Fees and Costs; Objective Evidence;
AND HUMAN SERVICES,         *                                    Reasonable Basis
                            *
                Respondent. *
                            *
*********************

Michael Avrim Firestone, Marvin Firestone, MD, JD and Associates, San Mateo, CA, for
Petitioner.

Heather Lynn Pearlman, U.S. Dep’t of Justice, Washington, DC, for Respondent.

                    DECISION DENYING ATTORNEY’S FEES AND COSTS 1

        On May 21, 2019, John and Marie Louise Heath filed a petition on behalf of their minor
son, J.N.H., seeking compensation under the National Vaccine Injury Compensation Program (the
“Vaccine Program”). 2 (ECF No. 1) (“Pet.”). They alleged that the Tdap (Adacel) vaccine J.N.H.

1
  Although this Decision has been formally designated “not to be published,” it will nevertheless be posted on the
Court of Federal Claims’s website in accordance with the E-Government Act of 2002, 44 U.S.C. § 3501 (2012)). This
means that the Decision will be available to anyone with access to the internet. As provided by 42 U.S.C. § 300aa-
12(d)(4)(B), however, the parties may object to the Decision’s inclusion of certain kinds of confidential information.
Specifically, under Vaccine Rule 18(b), each party has fourteen days within which to request redaction “of any
information furnished by that party: (1) that is a trade secret or commercial or financial in substance and is privileged
or confidential; or (2) that includes medical files or similar files, the disclosure of which would constitute a clearly
unwarranted invasion of privacy.” Vaccine Rule 18(b). Otherwise, the whole Decision will be available to the public
in its current form. Id.
2
 The Vaccine Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660,
100 Stat. 3758, codified as amended, 42 U.S.C. §§ 300aa-10 through 34 (2012) [hereinafter “Vaccine Act” or “the
Act”]. Individual section references hereafter will be to § 300aa of the Act.
received on June 1, 2016 caused autoimmune encephalitis which led to a permanent neurological
disability, or alternatively that it caused a significant aggravation of a preexisting autoimmune
disorder, autoimmune encephalitis, which later resulted in permanent neurological disability. Pet.
at 11. The case was dismissed last winter.

        Petitioners have now filed a fees application, requesting a total of $10,820.65 in fees and
costs for work performed from May 29, 2019, to September 18, 2020. Petitioner’s Application,
filed on Sept. 20, 2020 (ECF No. 24) (“Fees App.”). Respondent reacted and opposed Petitioner’s
application. Respondent’s Opposition, filed on October 5, 2020 (ECF No. 25). Respondent asserts
that Petitioners have “failed to establish a reasonable basis for” their claim. Id. at 1. Petitioners did
not file a reply.

        For the following reasons I DENY Petitioners’ motion for fees and costs, because I find
that their claim lacked reasonable basis from its inception.

I.         Procedural/Factual Background

         At the time of his June 2016 receipt of a Tdap booster, J.N.H. was a 13-year-old with a
history significant for multiple conditions including, autism spectrum disorder, anxiety, attention
deficit disorder, and obsessive-compulsive disorder (“OCD”). See Ex. 4 at 1-3; Ex. 6 at 205. Four
months later (with no intervening medical record evidence of any reaction or health problems that
temporally could be related to vaccination), in October 2016 J.N.H. was seen for complaints of
“tiredness and not feeling well”. Ex. 4 at 4. According to the record, this was “the same complaint
as last visit.” Id. J.N.H. returned to the doctor’s office on October 17, 2016 complaining of sore
throat. Id. at 8. The record reflects that J.N.H.’s father “was concerned about PANDAS,” 3 although
testing for strep was negative. In November 2016, J.N.H’s parents reported to treaters that his
behavior had gotten “exponentially worse” since his grandmother passed away earlier that month.
Id. at 9-13. Counseling and dietary changes were recommended. Id.

         In January of 2017, J.N.H. presented to a new primary care physician who was told that
J.N.H. had experienced an abrupt onset of neuropsychiatric symptoms one year earlier, right after
a strep throat infection (although if so this would predate the vaccinations at issue). Ex. 14 at 14.
The record from this visit noted a history of autism and social difficulties, but that J.N.H. had been
doing well until the onset of his more recent symptoms, which included severe anxiety and OCD.
Id. at 15-18.

       J.N.H.’s condition continued to decline over the next two years, which were filled with
multiple inpatient psychiatric hospitalizations, as well as emergency room visits. See generally Ex.
6. In April 2019, J.N.H. was seen for a flare in his behavior over the past two months. Id. at 826.
Although he was due to receive some vaccines, Petitioners refused based on concerns of the Tdap

3
    “PANDAS” stands for Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus infections.

                                                        2
vaccine having caused a vaccine injury, and the record of this visit records their intent at the time
to pursue a vaccine injury claim. Id. at 822, 826. On May 13, 2019, the treater in question wrote a
letter “To Whom it May Concern,” stating that it was highly likely in his view that the Tdap
vaccine administered in June 2016 caused J.N.H’s neurological illness and decline. Ex. 5 at 1.

        Because the vaccine in question was received in June 2016, Petitioners’ claim needed to
be filed sometime in the summer of 2019 (depending on the alleged onset) to be timely under the
Act’s 36-month limitations period. Section 16(a)(2). And indeed, the Petition expressly stated that
the matter was being filed expeditiously, in order to preserve the statute of limitations. Pet. at 1.
Once counsel had the opportunity to obtain and review medical records and additional information,
an amended petition was to be filed. Id. at 1-2.

        Petitioners filed some medical records in the two months following the case’s initiation,
and then a status conference was held on July 17, 2019. At that time, I expressed immediate
concerns regarding the claim’s overall reasonable basis, in light of the documented medical record
and based on my experience adjudicating highly-similar claims (and indeed - I scheduled the
conference as soon after filing of the Petition as possible, since the deficiencies in the claim jumped
out from my initial review). See Order, July 17, 2019 (ECF No. 8). In particular, I noted that
Petitioner’s theory (that J.N.H. suffered a severe encephalopathic reaction immediately following
receipt of the Tdap vaccine) lacked contemporary, corroborative record evidence. Id. at 1-2. I also
noted that it was very unlikely that Petitioners could prevail on a theory alleging a significant
aggravation of either J.N.H’s autism spectrum disorder (which the records clearly indicated he had
been diagnosed with) or any other purported injury. Id.

        On December 10, 2019—barely six months post-filing—Petitioners moved to withdraw
the petition pursuant to Vaccine Rule 21(b). This pleading was stricken, however, and on January
10, 2020, Petitioners filed a Motion for Ruling on the Record. Motion, filed on Jan. 10, 2020 (ECF
No. 16). Respondent reacted to Petitioner’s motion in a Response filed on February 12, 2020,
asserting that Petitioners failed to substantiate their claim and therefore are not entitled to
compensation. Response, filed Feb. 12, 2020 (ECF No. 19). On February 19, 2020, I issued a
decision denying entitlement in this matter. Decision, filed Feb. 19, 2020 (ECF No. 20).

II.    Analysis

A.     Reasonable Basis Standard

        I have in prior decisions set forth at length the criteria to be applied when determining if a
claim possessed “reasonable basis” sufficient for a fees award. See, e.g., Allicock v. Sec’y of Health
& Human Servs., No. 15-485V, 2016 WL 3571906, at *4–5 (Fed. Cl. Spec. Mstr. May 26, 2016),
aff’d on other grounds, 128 Fed. Cl. 724 (2016); Gonzalez v. Sec’y of Health & Human Servs.,
No. 14-1072V, 2015 WL 10435023, at *5–6 (Fed. Cl. Spec. Mstr. Nov. 10, 2015). In short, a
petitioner can receive a fees award even if his claim fails, but to do so he must demonstrate the

                                                  3
claim’s reasonable basis through some objective evidentiary showing. Simmons v. Sec’y of Health
& Human Servs., 875 F.3d 632, 635 (Fed. Cir. 2017); see also Chuisano v. Sec’y of Health &
Human Servs., 116 Fed. Cl. 276, 286 (2014) (citing McKellar v. Sec’y of Health & Human Servs.,
101 Fed. Cl. 303, 303 (2011)). The standard for reasonable basis is lesser (and inherently easier to
satisfy) than the preponderant standard applied when assessing entitlement, as cases with
reasonable basis (because they have objective proof supporting the claim) can nevertheless still
fail to establish causation-in-fact. Braun v. Sec’y of Health & Human Servs., 144 Fed. Cl. 72, 77
(Fed. Cl. 2019). 4

        The Federal Circuit recently clarified the standards used to evaluate whether a claim has
reasonable basis. Cottingham v. Sec’y of Health & Human Servs., 971 F.3d 1337 (Fed. Cir. 2020).
Although the “totality of the circumstances” in which a claim is filed is still a reasonable
framework, ultimately objective proof supporting the claim is required to establish reasonable
basis. Cottingham, 971 F.3d at 1344-45. Under that totality analysis, a special master should
consider “the novelty of the vaccine, scientific understanding of the vaccine and its potential
consequences, the availability of experts and medical literature, and the time frame counsel has to
investigate and prepare the claim” when considering whether objective proof exists in support of
the claim. Cottingham v. Sec'y of Health & Human Servs., 134 Fed. Cl. 567, 574 (2017).

        Reasonable basis—or the lack thereof—has been discussed in claims involving autism
spectrum disorders (“ASDs”). The Omnibus Autism Proceedings (“OAP”), which concluded in
2010, consistently determined that there was no persuasive evidence that the MMR vaccine or
thimerosal-containing vaccines caused autism. 5 Since then, cases bringing similar claims have
been uniformly rejected, and thus “Vaccine Act counsel [have been] put on notice” that if counsel
pursue, to a decision, theories linking vaccines causally to ASD, and their evidence proves to be
highly unpersuasive,” then special masters will find that the claim was brought without reasonable
basis. See, e.g., Sturdivant v. Sec’y of Health & Human Servs., No. 07-788V, 2016 WL 552529, at
*20 (Fed. Cl. Spec. Mstr. Jan. 21, 2016) (footnote omitted) (discussing the history of autism cases
in the Vaccine Program and how those cases have consistently fallen “far short of plausibility”
since the OAP concluded (emphasis in original)); Hardy v. Sec’y of Health & Human Servs., No.
08–108V, 2015 WL 7732603, at *33–35 (Fed. Cl. Spec. Mstr. Nov. 3, 2015); Long v. Sec’y of
Health & Human Servs., No. 08–792V, 2015 WL 11011740, at *19–20 (Fed. Cl. Spec. Mstr. Feb.
9, 2015). I myself have noted that counsel in vaccine injury cases run the risk of nonpayment for
bringing a claim relying, in whole or part, on autism-related symptoms as an injury. A.S. by Sterling

4
  There is also a good faith requirement that must be satisfied to obtain a fees award in an unsuccessful case, but here
I find that Petitioners proceeded with the matter in a good faith belief that their claim had merit.
5
 The Court of Federal Claims has also made it clear that petitioners cannot successfully recast a claim that a vaccine
caused autism into an encephalopathy claim, based on the logic that the neurologic symptoms associated with an ASD
reflect an underlying brain injury. See, e.g., Cunningham v. Sec’y of Health & Human Servs., No. 13–483V, 2017 WL
1174448, at *5 (Fed. Cl. Jan. 25, 2017).

                                                           4
v. Sec. of Health & Human Servs., No. 16-551V, 2020 WL 549443, at *5 (Fed. Cl. Spec. Mstr.
Jan. 3, 2020) (denying attorney’s fees and costs for alleged vaccine-caused autism injury).

B.     This Claim Lacked Reasonable Basis from the Date of Filing

       Because Petitioners were literally unsuccessful in bringing their claim, they must
demonstrate that the claim had reasonable basis if they are to be awarded attorney’s fees and costs.
I find that the claim lacked reasonable basis from its inception—and Petitioners have not
referenced evidence establishing the contrary.

       First, there is a total lack of evidence in the record establishing in any regard that J.N.H.
experienced a post-vaccination reaction that could be deemed to rise to the level of a severe brain
injury consistent with what the Petition alleges. Petitioners alleged that J.N.H. experienced
symptoms of an autoimmune encephalitis within hours of receiving the vaccine, when he
purportedly developed a fever within 24 hours of administration (Pet. at 6). But the record not only
does not permit a preponderant finding in that regard—it does not corroborate the allegation at all,
and instead better supports the conclusion that J.N.H. displayed no immediate, close-in-time
reaction. Certainly J.N.H. was not hospitalized or treated in the immediate weeks and months post-
vaccination. Petitioners’ reliance on a non-contemporaneous treater opinion letter, prepared for
pending litigation and unsupported by the medical records, can be afforded minimal weight at best.
See Opinion Letter, filed as Ex. 5 on July 16, 20219 (ECF No. 7-50) at 1. Petitioners otherwise
temporally associate J.N.H.’s subsequent symptoms (which do not appear to have manifested until
several months post-vaccination) with the Tdap vaccine he received in June 2016, but it is
axiomatic in the Program that a mere temporal relationship is never sufficient to obtain entitlement.
See Grant v. Sec. of Health & Human Servs., 956 F,2d 1144 (Fed. Cl. 1992) (holding that “a
proximate temporal associate alone does not suffice to show a causal link between the vaccination
and the injury”).

        There is also no record evidence of an encephalopathy diagnosis or anything that would
suggest such a diagnosis could have been appropriate. In rare cases petitioners have succeeded in
establishing a vaccine-caused encephalopathy that produced developmental regression or ASD-
like symptoms. But this occurred solely in the context of Table claims (where claimants are held
to exacting factual showings if causation is to be presumed), and the facts in such unique cases
underscore the importance of evidence of acute and/or immediate encephalopathy precipitated by
a close-in-time vaccination. See, e.g., Wright v. Sec’y of Health & Human Servs., No. 12-423V,
2015 WL 6665600, at *10 (Fed. Cl. Spec. Mstr. Sept. 21, 2015) (finding that a child with
developmental regression symptoms experienced a Table encephalopathy, where child convulsed
and vomited during car ride home after receiving vaccinations (possibly evincing a brief seizure),
then became listless, unresponsive, and “basically catatonic” by the following day); Bast v. Sec’y
of Health & Human Servs., No. 01-565V, 2012 WL 6858040, at *35–36 (Fed. Cl. Spec. Mstr. Dec.
20, 2012) (discussing case report involving a successful Vaccine Program claimant who alleged a

                                                 5
Table encephalopathy claim for her autism-type symptoms; child had developed a high fever,
inconsolable crying, irritability, and lethargy, and refusal to walk within forty-eight hours after
vaccination), mot. for review den’d, 117 Fed. Cl. 104 (2014), aff’d, 579 F. App’x 1001 (Fed. Cir.
2014). This case does not establish Table liability (and does not in fact attempt to do so).

        Second, Petitioners have pursued a kind of claim (here, relying on exacerbation of autism
symptoms) that has been repeatedly, unsuccessfully interposed in the Program. As noted, even
after the OAP determined that specific, more narrow causation theory involving ASD as a vaccine
injury had failed, numerous other claims, seeking to set themselves apart from the causation
theories in the OAP, experienced the same result. See, e.g., Rogero v. Sec’y of Health & Human
Servs., No. 11-770V, 2017 WL 4277580, at *4–5 (Fed. Cl. Spec. Mstr. Sept. 1, 2017) (citing
eighteen unsuccessful post-OAP autism claims that went to hearing, and thirteen post-OAP autism
claims that were rejected without a hearing), mot. for review denied, slip op. (Fed. Cl. Jan. 11,
2018), aff’d, 748 F. App’x 996 (Fed. Cir. 2018). Since then, special masters (including me) have
reasonably questioned whether such autism injury claims could still be brought with reasonable
basis. See, e.g., Hashi v. Sec’y of Health & Human Servs., No. 08-307V, 2016 WL 5092917 (Fed.
Cl. Spec. Mstr. Aug. 25, 2016); Sturdivant, 2016 WL 552529, at *20. This evolved into explicit
warnings—that such claims would lack reasonable basis unless they could be set apart from
previously decided claims by persuasive evidence. Hooker v. Sec’y of Health & Human Servs.,
No. 02-472V, 2017 WL 3033940, at *7–8, 22 (Fed. Cl. Spec. Mstr. Apr. 11, 2017).

       Given this context, it was critical for counsel to carefully evaluate the objective factual
basis for the claim prior to its filing. But this did not occur—and counsel in question is an
experienced Vaccine Program bar member, having practiced in the Program for many years. See
Fees App. at 3. While counsel may not have had a great deal of time to perform such due diligence,
the burden of doing so falls on counsel—and more importantly, the Federal Circuit has explicitly
ruled that a looming limitations cut-off does not constitute objective support for a claim,
eliminating it as a factor that can justify the filing of a claim that otherwise lacks reasonable basis.
Simmons, 875 F.3d at 636. The explicit deficiencies in this kind of petition were, or should have
been, known to Petitioners and their counsel at the time the claim was filed.

        I am reluctant to deny fees in any Vaccine Act claim in their entirety, and in most cases
endeavor to find some basis for at least a partial fees award. See, e.g., Curran v. Sec’y of Health &
Human Servs., No. 15-804V, 2016 WL 4272069, at *3 (Fed. Cl. Spec. Mstr. June 22, 2016)
(awarding partial attorney’s fees; claim had reasonable basis upon filing, but lost it after a certain
date), aff’d in part, 130 Fed. Cl. 1, 8 (Fed. Cl. 2017) (affirming findings with respect to reasonable
basis). It is especially hard to do so when dealing with attorneys who regularly provide competent
service to their clients in the Vaccine Program. But the nature of this claim, in conjunction with
the matter’s procedural history, do not support such lenience here. This claim should not have been
filed.

                                                   6
                                        CONCLUSION

       Based on my review of the factual and procedural history I conclude that this claim was
unsupported by objective factual basis or medical support. Further, Petitioners were on notice of
deficiencies in their case early on, but proceeded regardless. As a result, Petitioners never had a
reasonable basis for their claim, and their motion for attorney’s fees and costs is DENIED.

       IT IS SO ORDERED.
                                                             /s/ Brian H. Corcoran
                                                              Brian H. Corcoran
                                                              Chief Special Master

                                                7